Wednesday 20th November 2019, 11:30 – 14:00
Advanced therapeutics refer to medicines based on genes, tissues and cells. They offer new opportunities for treatments in areas of high un-met needs.
In order to adopt these medicines into standard healthcare, there needs to be consideration of the differences to pharmaceuticals and biologics and the significantly more complicated supply chain that they require. This includes challenges around shelf-life of therapies, manufacturing close to treatment, feasibility of large batches and reducing costs, to name but a few.
Our BioWednesday will look at the manufacturing challenges that we need to tackle in order to deliver advanced therapies to patients. It will feature examples of excellence that are helping to scale-up manufacturing and ultimately help to implement these therapies in the long term for greater numbers of patients.
11.30 Registration and networking over tea and coffee
12.00 Intro to SBC
12.10 Presentations from Manufacturers and Therapeutics Organisations on how they’re accelerating cell and gene therapies, particularly focusing on the manufacturing challenges they feel they are addressing, lessons learnt and things to consider when scaling from pre-clinical to clinical.
• Matthew Miell, Viral Vector Group Leader, GE Healthcare
• Sharon Brownlow, Head of Collaborations - Manufacturing Centre, Cell & Gene Therapy Catapult
• Joanna Vlahopoulou, Founder, Procellia
• Dara Henry, VP Operations and Business Development, Achilles Therapeutics Ltd
13.15 Lunch / Round table discussions with presenting organisations
One Nucleus Members: Free
Non-Members: £50 +VAT
Academics: please contact firstname.lastname@example.org